Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s Bayesian Alzheimer’s Trial Aims For Quick Proof Of Concept With Fewer Subjects, Lower Cost

Executive Summary

Eisai should get the first feedback from an adaptive Phase II trial of BAN2401 in Alzheimer’s patients with mild cognitive impairment in six or seven months, offering the first opportunity to adjust parameters testing dose response and the antibody’s disease-modifying potential or to stop the trial early for futility.

You may also be interested in...

Adaptive Trials Guidance For Pediatric Drugs Will Draw On Device Advice

FDA’s centers may slingshot development work on how best to use control data.

Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up

The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.

Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says

A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts